Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Mouse PD-1 / PDCD1, Fc Tag, Avi Tag (Avitag™), 200µg  

Recombinant Biotinylated Mouse PD-1 / PDCD1, Fc Tag, Avi Tag (Avitag™), 200µg

MABSol® Recombinant Biotinylated Mouse PD-1 / PDCD1, Fc Tag, expressed from human HEK293 cells, Fc Tag, Avi tag (Avitag™)

Synonym
recombinant, mouse, biotinylated, protein, PDCD1,PD1,CD279,SLEB2

More details

PD1-M82F4-200

Availability: within 7 days

1 380,00 €

Background
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Source
MABSol® Biotinylated Mouse PD-1, Fc Tag (PD1-M82F4) is expressed from human HEK293 cells. It contains AA Leu 25 - Gln 167 (Accession # NP_032824).
Predicted N-terminus: Leu 25

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).
The protein has a calculated MW of 44.6 kDa. The protein migrates as 60-75 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>92% as determined by reduced SDS-PAGE. 

Bioactivity
Please refer to product data sheet.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Reconstitute at 100 μg/mL in sterile deionized water. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. No activity loss is observed after storage at: 4-8°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrosbiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.

References

(1) Ishida Y., et al., 1992, EMBO J. 11 (11): 3887–95.
(2) Blank C., et al., 2007, Cancer Immunol. Immunother. 56 (5): 739–45.
(3) Agata Y., et al., 1996, Int. Immunol. 8 (5): 765–72.
(4) Freeman GJ., et al., 2000, J. Exp. Med. 192 (7): 1027–34.
(5) Latchman Y., et al., 2001, Nat. Immunol. 2 (3): 261–8.
(6) Yamazaki T., et al., 2002, J. Immunol. 169 (10): 5538–45.

The following products could also be interesting for you: